We did not develop this medicine for Indians. We developed it for western patients who can afford it.
— Bayer CEO Marijn Dekkers • Explaining, rather bluntly, why he feels that India’s efforts to genericize the company’s uber-expensive cancer drug Nexavar is wrong. Now where that falls on the scale of wrong that leads the CEO of a multibillion-dollar company to say that giving cancer drugs to people who are not rich is wrong, I’m not sure. But either way, let’s call this guy a prick, especially since said drugs would cost a person who lives in India $65,000 per year.